source
- Innoviva revives Lyndra's long-acting oral drug platformInnoviva, a healthcare asset and royalties holding firm, announced it is bringing back Lyndra's long-acting oral drug delivery platform. The technology, which previously attracted more than $380 mi…
- Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…